Diabetic retinopathy clinical trials

Explore recruiting diabetic retinopathy clinical trials.

Recruiting diabetic retinopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Diabetic retinopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

(Neo)adjuvant IDE196 (Darovasertib) in Patients with Localized Ocular Melanoma

Italy, France, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS)

Portugal, Poland, Spain, Romania, Czechia, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)

Czechia, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 (Vonaprument) Administered by Intravitreal Injection in Participants with Dry Age-Related Macular Degeneration with Geographic Atrophy

Italy, France, Poland, Germany, Hungary, Spain +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

Czechia, Bulgaria, Croatia, Netherlands, Poland, Estonia +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Germany, Portugal, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Diabetic retinopathy trials by city

Diabetic retinopathy in Toronto Diabetic retinopathy in Vancouver Diabetic retinopathy in Montreal Diabetic retinopathy in Calgary Diabetic retinopathy in Edmonton Diabetic retinopathy in Ottawa Diabetic retinopathy in Winnipeg Diabetic retinopathy in Quebec City Diabetic retinopathy in Hamilton Diabetic retinopathy in Kitchener Diabetic retinopathy in London Diabetic retinopathy in Halifax Diabetic retinopathy in New York Diabetic retinopathy in Los Angeles Diabetic retinopathy in Chicago Diabetic retinopathy in Houston

Other conditions

Leukemia Lymphoma Multiple myeloma Bladder cancer Kidney cancer Liver cancer Glioblastoma Head and neck cancer Cervical cancer Endometrial cancer Gastric cancer Age-related macular degeneration Glaucoma Dry eye disease HIV Hepatitis B Hepatitis C COVID-19 Influenza RSV Sickle cell disease Anemia Hemophilia Thalassemia